Antimicrobial resistance (AMR) in gram-negative bacteria (GNB) is persisting to be a significant cause of severe infections across the world, with increasing morbidity and mortality rates. Extended spectrum beta lactamase (ESBL) rates are alarmingly increasing in Escherichia and Klebsiella species, which is about 70% and there has been an increase in the resistance to carbapenems over the past few years in India. Current scenario of rapidly growing multidrug resistant (MDR) organisms in our Indian intensive care units is posing difficulties with regard to detecting these infections and starting appropriate empirical antibiotics. A clear understanding of the epidemiological, microbiological, and pharmacological aspects of these MDR gram-negative organisms is very important. This article tries to brief the risk factors for MDR GNB infections, spectrum of MDR GNB infections, mechanisms of resistance, and beta-lactamase enzyme classification and outlines the clinically important types and the treatment considerations for these MDR gram-negative organisms.
EpIdEmIology
Study for monitoring antimicrobial resistance trends (SMART) which was done during 2004 shows that ESBL-producing bacteria were highest in Latin America, the Middle East, Africa, and Asia. 6 The SMART has showed that prevalence of cephalosporin resistance mediated by ESBL) production in Escherichia coli and Klebsiella pneumoniae is 40.8% and 21.5%, respectively, in the Asia-Pacific region. 7 Community-acquired urinary tract infections (UTIs) caused by ESBL-producing E. coli which are resistant to cephalosporins and fluroquinolones are increasing in the US, Europe, and Asia. [8] [9] [10] In 2007, the prevalence of community-acquired ESBL-producing E. coli infections is as common as hospital-acquired ones and 79% of the E. coli isolates tested were ESBL producers ( Table 1) . 11 Why do we have so much of MDR organisms?
• Decades of overuse and misuse of antibiotics.
• Excess use of antibacterial products by the public over the counter and animal industry. • Inappropriate antibiotic therapy. • Hospital-acquired infections: invasive procedures, prolonged hospitalization, and previous use of cephalosporins and fluoroquinolones. 13 • Risk factors for carbapenemase-producing Klebsiella pneumoniae infections are the following:
Severe underlying disease, diabetes mellitus, ICU admission, mechanical ventilation, and exposure to betalactams, and fluoroquinolones. 14, 15 
Definitions of MDR, Extensively Drug Resistance, and Pan Drug Resistance 16
• MDR: the isolates are not susceptible to at least one antibiotic in three or more antimicrobial categories. • Extensively Drug Resistance (XDR): the isolates are not susceptible to at least one antibiotic in all but two or fewer antimicrobial categories (i.e., they are susceptible to only one or two categories). • Pan Drug Resistance (PDR): the isolates are not susceptible to all antibiotics in all antimicrobial categories (i.e., no agents tested as susceptible for that organism).
Mechanisms for AMR in MDR GNB
GNB can adopt various mechanisms of resistance to a single class or to multiple classes of antibiotics, as depicted in Table 2 . Beta-lactamase production is the most important mechanism of resistance to betalactams adopted by GNB, and beta-lactamase enzymes break the amide bond of the betalactam ring and inactivates the betalactams. 17
Amblers Classification of ESBLs 18,19
Beta lactamases are classified based on their molecular structure and aminoacid pattern.
There are four classes: Classes A, C, and D have serine at their active site, and class B beta lactamases are also called MBLs as they have zinc at their active site. 17 
Class A
These ESBLs are plasmid mediated, and they inhibit all penicillins and cephalosporins (except cephamycins) and aztreonam; b-lactamase inhibitors can inhibit these enzymes. There are mainly three groups in class A: TEM, SHV and CTX-M, and TEM and SHV are active against ceftazidime than cefotaxime and were predominant during the 1980s and 1990s; and CTX-M are more active against cefotaxime, and they are now the most frequent ESBLs worldwide since 1990s. 20 In India, CTX-M-mediated ESBLs are more common, followed by TEM and SHV. 3 Klebsiella pneumoniae carbapenemases (KPCs) also belong to class A enzymes, and they can hydrolyze the carbapenems. 21 
Class B
They are also called MLBs, and they are active against penicillins, cephalosporins, and carbapenems. Monobactams (aztreonam) are not affected.
Important types of MLBs are IMP, VIM, and NDM. 21 In India, carbapenem-resistant E. coli and Klebsiella spp. are mainly due to the presence of MBLs NDM-1. 3
Class C
AmpC enzymes are the most important ESBLs in this class.
These enzymes are constitutively produced by several enterobacteria like Enterobacter species, Citrobacter freundii, Serratia marcescens, Morganella, Proteus, and Providentia. Class C betalactamase genes are also present in transferable plasmids. 22 They inhibit penicillins and cephalosporins except cefepime and are not inhibited by b-lactamase inhibitors. The AmpC enzyme-producing gene is inducible, and normally it is suppressed and not detected in vitro, but in vivo it can cause resistance. 22, 23 Classes B and C ESBLs have a broad spectrum of activity and they were always encoded by chromosomal genes, and hence, they are confined to a particular bacterial species. 17 
Class D
Oxacillinases are the most important enzymes in this class, and they hydrolyze oxacillin efficiently, hence the name. They inhibit aztreonam and carbapenems. The clinically important oxacillinases are OXA-48 and OXA-181. OXA-48 has spread widely among various enterobacteria, and it is very active against imipenem. OXA-48 is usually produced along with an ESBL. 24 Summary of b-lactamases is given in Table 3 .
Carbapenem Resistance
Carbapenemase enzyme production is the important resistance mechanism against carbapenems.
Carbapenemases are ESBLs which can inhibit broad-spectrum betalactams antibiotics, like penicillins, cephalosporins, and carbapenems. 26 There are specific ESBLs in all the classes which has the ability to hydrolyze carbapenems.
In class A, KPCs are clinically very important. They inhibit all betalactams, and as they are plasmid-based, they are easily transferred to other gram-negative species, such as Escherichia coli, Enterobacter, Pseudomonas, and Salmonella. 26 In class B, clinically important enzymes are the IMP, VIM, SPM, and NDM. 17 The New Delhi MBL (NDM-1) is very important in Indian perspective. It was first isolated from a Swedish patient hospitalized with K. pneumoniae infection in India in 2008, since then they have been reported in the US and UK primarily associated with travel history to India or Pakistan. 27, 28 They inhibit all betalactams except aztreonam. They reside on mobile gene cassettes inserted into integrons which harbor additional antibiotic resistance genes leading to MDR. These genes are transferred to other species via transposons and plasmids. 23, 29 In class D, clinically important enzymes are OXA family, 30 and they are found primarily in P. aeruginosa and Acinetobacter species. 26 VIM (37%), NDM (17%) in Pseudomonas aeruginosa and OXA-23 (98%), and NDM (22%) in Acinetobacter baumannii are the most prevalent carbapenemases noted in India. 31 Other resistance mechanisms against carbapenems are impermeability and efflux, and these are common in Pseudomonas species. 35 
Fluoroquinolone Resistance
They acquire fluroquinolone resistance by altering the drug targets (DNA gyrase and/or topoisomerase IV) and also by efflux pumps especially in E. coli 1 and Pseudomonas aeruginosa. 32 
Aminoglycoside Resistance
They acquire aminoglycoside resistance by producing inactivating enzymes which can cause phosphorylation, adenylylation, or acetylation.
Alternatively, methylation of the 16S rRNA drug target causes resistance to the entire aminoglycoside class, including novel aminoglycosides. 33 These methylases are plasmid-mediated and are spread among GNB along with carbapenemases leading to MDR. 34 
Multidrug Resistance
GNB can activate several mechanisms at a time, like ESBL production, loss of porin channels, efflux pumps when they are exposed to an antibiotic leading to MDR. Transfer of plasmids with ESBL genes and other inactivating enzyme genes leads to the development of MDR strains. Pseudomonas aeruginosa and Acinetobacter baumannii most likely to become MDR in this fashion. 35 
Common Infections caused by GNB
Blood stream infections (BSIs), ventilator-associated pneumonias (VAP), intra-abdominal infections (IAIs), skin and soft tissue infections, and urinary tract infections (UTIs) are the most commonly encountered infections. 2 The epic 2 study showed that lungs are the most common site (64%), followed by abdominal infection (19%) and BSI (15%). 36 
When should We suspect ESBL and Carbapenemaseproducing GNB?
Based on antibiogram, if the isolate is resistant to third and fourth generation cephalosporins but sensitive to beta-lactamase inhibitors (Tazobactam), ESBL production should be suspected. If the isolate is resistant to carbapenems also, carbapenemase production has to be suspected. 26 Most Klebsiella and E. coli without carbapenemases have minimal inhibitory concentrations (MICs) to imepenem and meropenem that are <0.5 μg/mL. Overt resistance of Klebsiella and E. coli to any of the carbapenems should arise suspicion of carbapenemase producers.
Treatment of MDR GNB
Early suspicion of MDR GNB by risk factors and timely initiation of appropriate antibiotic is very important step in treating these infections, and it decreases the mortality and improves the survival rate. 37, 38 Starting with broad-spectrum antibiotics and once the susceptibility report is available the antibiotics has to be optimized to more appropriate and narrow spectrum. 38
Empirical Therapy
Local institutionwise antibiograms have to be prepared based on the local prevalence of MDR organisms, 39 and based on susceptibility patterns, broad-spectrum antibiotics or combination of antibiotics has to be started empirically after obtaining appropriate cultures. 26 As susceptibility rates to cephalosporins are severely decreasing, cephalosporins should not be a preferable choice for empirical therapy. 3 Carbapenems are the treatment of choice for empirical therapy of severe infections caused by ESBL-producing organisms. 40 
Current Treatment Options for treating MDR GNB Infections

Carbapenems (Meropenem and Imepenem)
Carbapenems are the drug of choice for treating life-threatening infections caused by ESBL-producing GNB. Studies have shown that 2-week mortality in patients with Klebsiella pneumoniae. BSI treated with meropenem was very less compared to other betalactam antibiotics. 41 Carbapenems have wide distribution in different sites of the body like lung, blood, urine, and cerebrospinal fluid. 42 They act in time-dependent bacterial fashion; 40-50% of the time, the drug levels have to be above the MIC. 42 As they are excreted unchanged through kidney, to maintain their concentration constantly above MIC, they can be administered as continuous infusion. 43 For treating susceptible KPC-producing Klebsiella infection, colistin and meropenem combination can be used when the MIC is 8 mg/L and prolonged meropenem infusion should be considered if the MIC is >8 but <32 mg/L. 44 
Polymyxins
Polymyxins are bactericidal agents which act on outer membrane of GNB.
They bind with the anionic lipopolysaccharide molecules by displacing calcium and magnesium from the outer cell membrane, leading to permeability changes in the cell envelope, leading to leakage of cell contents and cell death. 45 Colistin (polymyxin E) and polymyxin B are in wide usage, and colistin is parentrally available in the form of colistimethate sodium (CMS) which gets hydrolyzed to colistin and sulfomethylated derivatives once it enters the body. It acts in a concentrationdependent fashion and is excreted through kidney. 45
Colistin-loading Dose
As discussed earlier, the parentral CMS has to get converted to active colistin which is slow process, and colistin kills the bacteria in a concentration-dependent fashion. In view of large volume of distribution in critically ill patients and as the half-life of colistin is 2-3 days, it is important to give colistin-loading dose to achieve higher concentrations rapidly. 46, 47 The loading doses do not affect kidney function, but the maintenance doses have to be adjusted depending on the kidney function. 48 Colistin nebulization should be used in addition to intravenous therapy in patients with VAP due to MDR GNB. 49 Colistin combination therapy: colistin with meropenem combination had better outcome than any other combination with colistin. MIC for colistin and meropenem combination is 0.12 μg/mL, which is fivefold less when compared to meropenem 4 μg/mL and colistin 0.38 μg/mL when tested as single agents. 50 Colistin can be combined with amikacin or tigecycline in treating carbapenem-resistant GNB infections if they are sensitive to these antibiotics. 44 Fosfomycin Similar to colistin fosfomycin is also an old broad-spectrum bactericidal antibiotic, which acts on bacterial cell wall by interfering with formation of UDP N-acetylmuramic acid, a peptidoglycan precursor. It is used in treating MDR GNB infections often in combination with other agents when there are no alternatives. 51 
Tigecycline
It is a newer agent in tetracycline class which has shown good activity against CRE. Pseudomonas aeruginosa is inherently resistant to tigecycline. 52 Tigecycline rapidly redistributes into tissues and achieves low serum levels; hence, it is not useful in treating BSIs and VAP. 53 Food and Drug Administration (FDA) has approved tigecycline only in the treatment of soft tissue infection and IAIs caused by MDR GNB. 44 Eravacycline It is newer drug structurally similar to tigecycline, and it has been approved by FDA and European Medicines Agency (EMA) approved for the treatment of complicated IAIs (cIAIs). It is not affected by efflux pumps and ribosomal alterations by the GNBs, which is unique when compared to other tetracyclines. It has in vitro activity against KPCproducing bacteria and also acenatobacter baumannii. It has 90% oral bioavailability and also available in intravenous preparation. It has broad-spectrum of action covering gram-positive, GNB, and anaerobic bacteria except Pseudomonas and burkholdaria. 54 
Plazomicin
It is a newer aminoglycoside, and it stable against several aminoglycoside-modifying enzymes. It is active against CRE.
It is currently approved by the FDA for the treatment of complicated UTI (cUTI). 55
Ceftazidime/Avibactam
This combination has been approved by FDA and EMA for cUTIs, cIAIs, hospital-acquired pneumonia (HAP), and VAP. Studies showed a lower 30-day mortality with this combination for treating bacteriemia caused by KPC-producing Klebsiella isolates. 56 Hence, ceftazidime/avibactam is an effective option for the treatment of CRE. This combination is available in India.
Meropenem/Vaborbactam
It is another new BL-BLI, and it has a potent activity against class A (e.g., KPC) carbapenemase-producing CRE. It is FDA and EMA approved for cUTI, cIAI, HAP, and VAP in adult patients with limited treatment options. 57 Ceftolozane/tazobactam: it is another newer BL-BLI, and it is effective against Pseudomonas infections, but it is not active against CRE. It is approved by FDA and EMA for the treatment of cIAI and cUTI. 58, 59 
Proposed Treatment Options for MDR-GNB Infections in Critically Ill Patients 57
Current Treatment Options for CRE
KEy poInts
• Incidence of carbapenemase-producing GNB infections are rapidly growing in Indian ICUs, especially NDM-1-producing gram negatives. • Assessment of risk factors, MIC testing, and proper interpretation of antibiogram are vital in identifying these ESBL carbapenemaseproducing and MDR GNB. • Carbapenems are the drug of choice in treating serious infections caused by ESBL producers and are advised at high doses for carbapenemase-producing organisms (Klebsiella spp.) in combination with colistin as empirical therapy. • Colistin is the backbone agent in treating carbapenem-resistant Acinetobacter baumannii, and loading dose has to be given to reach adequate drug concentration in critically ill patients. • Inhaled colistin is advised in treating VAP along with intravenous colistin. • Newer agents like plazomicin, eravacycline, fosfomycin, and BL-BLI combinations can be combined with colistin and meropenem for treating carbapenemase producers.
conclusIons
• All hospitals should have their own institutional antimicrobial stewardship program, and it should be based on local antibiograms and international guidelines to prevent the emergence of MDR GNB and even a more complex situation. • Infection control practices should be strictly implemented to prevent MDR GNB infections in ICUs. • Differentiate true infection from colonization and avoid unnecessary antibiotic prescriptions. • Suspect MDR GNB infections and start adequate empirical antibiotics as soon as possible as delay in starting appropriate antibiotic is associated with poor outcomes. • Deescalate to appropriate antibiotic as soon as the sensitivity pattern is available.
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